Amyotrophic lateral sclerosis

36 trials 13 recruiting MedDRA PT
36 Registered trials
13 Recruiting
31 Unique sponsors
24 Unique IMPs
30 Commercial trials
Drug classes (ATC)
— ATC code not specified 33
L Oncology (ATC L) 2
N Neurology/Psychiatry (ATC N) 2
B Haematology (ATC B) 1
H Endocrinology (ATC H) 1
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 16 substances
Antisense oligonucleotide 2 substances
Kinase inhibitor 1 substance
Corticosteroid 1 substance
Analgesic / antipyretic 1 substance
Monoclonal antibody (chimeric) 1 substance
Supportive / diluent 1 substance
Antiviral 1 substance
Phase III: 6 Phase II/III: 1 Phase II: 10 Phase I/II: 4 Phase I: 5 Phase I (Other): 8 Phase I (First in Human): 2

Filter these 36 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 36 trials

Phase III

6 trials
  • Ab Science Commercial
    MASITINIB; RILUZOLE
    2024-511244-12-01 7 countries n=135 Orphan
    Suspended
  • Amylyx Pharmaceuticals Inc. Commercial
    PHENYLBUTYRATE, URSODOXICOLTAURINE
    2023-508511-23-00 10 countries 2021 n=526 Orphan
    Ended
  • Biogen Idec Research Limited Commercial
    TOFERSEN
    2023-505641-12-00 6 countries 2021 n=30 Orphan
    Ended
  • Ferrer Internacional S.A. Commercial
    PRIDOPIDINE HYDROCHLORIDE
    2025-524002-16-00 9 countries 2026 n=420 Orphan
    Recruiting
  • Stichting TRICALS Foundation Academic
    IMP not specified
    2024-516559-41-00 4 countries n=75
    Ended
  • Stichting TRICALS Foundation Academic
    ABACAVIR SULFATE, LAMIVUDINE, DOLUTEGRAVIR SODIUM
    2024-517054-94-00 5 countries 2021 n=119
    Ended

Phase II/III

1 trial
  • Ionis Pharmaceuticals Inc. Commercial
    ULEFNERSEN
    2024-512163-31-00 8 countries 2022 n=57
    Ended

Phase II

10 trials
  • AL-S Pharma AG Commercial
    ANTI-(MISFOLDED HUMAN SUPEROXIDE DISMUTASE 1) HUMAN IGG1M3 MONOCLONAL ANTIBODY
    2024-512343-23-00 1 country 2022 n=5 Orphan
    Ended
  • Argenx Commercial
    ADIMANEBART
    2024-511318-19-00 5 countries 2024 n=49
    Ended
  • Corcept Therapeutics Inc. Commercial
    DAZUCORILANT
    2024-514082-19-00 7 countries 2022 n=240
    Ended
  • Novartis Pharma AG Commercial
    VHB937
    2024-512536-29-00 11 countries 2025 n=121
    Recruiting
  • Phenonet Inc. Commercial
    SODIUM CROMOGLICATE
    2025-520688-42-00 4 countries 2026 n=123
    Recruiting
  • PTC Therapeutics Inc. Commercial
    UTRELOXASTAT
    2023-510317-26-00 11 countries 2023 n=242 Orphan
    Ended
  • Zydus Therapeutics Inc. Commercial
    USNOFLAST
    2025-522580-15-00 9 countries n=206 Orphan
    Pending
  • Casa Sollievo Della Sofferenza Academic
    IMP not specified
    2024-518888-35-00 1 country 2024 n=30
    Recruiting
  • Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V. Academic
    METHYLPREDNISOLONE HYDROGEN SUCCINATE; PARACETAMOL; RITUXIMAB; SODIUM CHLORIDE
    2022-502743-35-00 1 country 2024 n=52
    Recruiting
  • Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia Academic
    IMP not specified
    2023-506215-17-00 1 country 2021 n=100
    Recruiting

Phase I/II

4 trials
  • Nura Bio Inc. Commercial
    NB-4746; RILUZOLE
    2025-523939-18-00 2 countries n=28
    Pending
  • Sanofi-Aventis Research & Development Commercial
    SAR443820
    2022-502534-23-00 1 country 2023 n=6
    Ended
  • uniQure biopharma B.V. Commercial
    ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 ENCODING MIRNA AGAINST SOD1 MRNA
    2024-517244-57-00 1 country 2025 n=5 Orphan
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-513471-40-00 1 country n=23
    Pending

Phase I

5 trials
  • AC Immune S.A. Commercial
    IMP not specified
    2024-513097-21-00 1 country 2024 n=45
    Recruiting
  • Eli Lilly & Co. Commercial
    IMP not specified
    2025-521295-60-00 4 countries 2026 n=30
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2023-506946-21-00 1 country 2023 n=24
    Ended
  • Molefy Pharma S.L. Commercial
    IMP not specified
    2025-524480-21-00 1 country 2026 n=72
    Recruiting
  • Projenx Inc. Commercial
    IMP not specified
    2023-507363-20-00 1 country 2024 n=14
    Ended

Phase I (Other)

8 trials
  • Itb-Med AB Commercial
    IMP not specified
    2023-506174-12-00 1 country 2025 n=57
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-511405-27-00 1 country 2024 n=32
    Ended
  • Mitochon Pharmaceuticals Inc. Commercial
    IMP not specified
    2023-507195-43-00 1 country 2024 n=40
    Recruiting
  • Quralis Corp. Commercial
    IMP not specified
    2024-513127-16-00 1 country 2024 n=60
    Ended
  • Quralis Corp. Commercial
    IMP not specified
    2024-515021-29-00 1 country 2024 n=12
    Ended
  • Quralis Corp. Commercial
    IMP not specified
    2024-518833-27-00 1 country 2025 n=24
    Ended
  • Quralis Corp. Commercial
    IMP not specified
    2025-524310-28-00 1 country 2026 n=48
    Recruiting
  • Tranquis Therapeutics Inc. Commercial
    IMP not specified
    2023-504746-54-00 1 country n=16
    Pending

Phase I (First in Human)

2 trials
  • Leal Therapeutics Inc. Commercial
    LTX-002 SODIUM
    2025-522039-33-00 4 countries 2026 n=30
    Recruiting
  • VectorY Therapeutics B.V. Commercial
    SODIUM DIHYDROGEN PHOSPHATE DIHYDRATE; VTX-002
    2025-522697-37-00 3 countries n=4
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Quralis Corp. Commercial 4 Phase I (Other) 1
Merck Sharp & Dohme LLC Commercial 2 Phase I, Phase I (Other) 0
Stichting TRICALS Foundation Academic 2 Phase III 0
AC Immune S.A. Commercial 1 Phase I 1
Eli Lilly & Co. Commercial 1 Phase I 1
Molefy Pharma S.L. Commercial 1 Phase I 1
Projenx Inc. Commercial 1 Phase I 0
Ionis Pharmaceuticals Inc. Commercial 1 Phase II/III 0
Itb-Med AB Commercial 1 Phase I (Other) 1
Mitochon Pharmaceuticals Inc. Commercial 1 Phase I (Other) 1
Tranquis Therapeutics Inc. Commercial 1 Phase I (Other) 0
AL-S Pharma AG Commercial 1 Phase II 0
Argenx Commercial 1 Phase II 0
Corcept Therapeutics Inc. Commercial 1 Phase II 0
Novartis Pharma AG Commercial 1 Phase II 1
Phenonet Inc. Commercial 1 Phase II 1
PTC Therapeutics Inc. Commercial 1 Phase II 0
Zydus Therapeutics Inc. Commercial 1 Phase II 0
Ab Science Commercial 1 Phase III 0
Amylyx Pharmaceuticals Inc. Commercial 1 Phase III 0
New trials by year
2021
4
2022
3
2023
3
2024
9
2025
4
2026
6
← All indication landscapes